The Acceleration Arrives: Abbott Beats, Raises, and Rips 11% as the Ex-Deal Growth Question Resolves

Results vs. Consensus

Q2 2026 Scorecard

Year-Over-Year & Sequential

Quality of Result

Revenue: The +13.0% reported figure is inflated by the Exact Sciences consolidation and ~0.8% of FX; the number that matters is the +4.8% comparable rate, which folds Exact Sciences into both years and strips the currency. That rate accelerated from +3.7% in Q1, and management was explicit that the monthly cadence improved through the quarter, so the exit rate is higher than the quarterly average. The composition is broad: Established Pharmaceuticals +8.7%, Medical Devices +8.4%, Cancer Diagnostics +13.3%, with the drags isolated to a still-negative Nutrition line and the seasonal Rapid/Molecular decline. The Q1 worry was that the legacy franchise had structurally decelerated toward 6%; this print is the first hard evidence the step-down was transitory rather than permanent.

Margins: Adjusted gross margin of 58.0% expanded 100bp year-over-year and 170bp sequentially, the cleanest margin signal in several quarters. Management attributed it to three durable sources (favorable mix within legacy Abbott, the accretive Exact Sciences addition, and the standing cost and margin-expansion programs) rather than a one-time benefit, and folded that confidence into the guidance raise. R&D ran 6.9% of sales and SG&A 28.5%, both consistent with the operating-leverage algorithm. After a Q1 in which the gross-margin line went flat and gave the bears an opening, this is the pillar being rebuilt in real time.

EPS: The $1.31 (+4.0% YoY) beat the $1.28 Street and cleared the guided midpoint. The headline 4% growth rate understates the underlying algorithm for the same mechanical reason it did in Q1: roughly $0.05 of quarterly Exact Sciences dilution is flowing through the year-over-year comparison. Ex-deal, the underlying earnings growth remains consistent with the double-digit target, which is why management could raise the full-year number even as the reported quarterly growth optically looks modest. There is no below-the-line help in this print; it is an operational beat.

Segment Performance

Medical Devices: Electrophysiology Leads, Structural Heart Turns, CGM Steady

Medical Devices grew 8.4% comparable to $5.853B, led again by the cardiovascular franchise. Electrophysiology was the standout at +13.4%, with the next-generation Bolt PFA catheter (Bolt 2.0) launched in the U.S. in May and set to move from a limited to a full market release in Q3, while Europe EP grew more than 20% on the broadening Bolt and TactiFlex Duo rollout. The foundational franchises compounded (Rhythm Management +9.5%, Heart Failure +8.7%), and Diabetes Care grew 9.0% with CGM specifically above $2.0B and up 9.5%. The most encouraging change from Q1 is Structural Heart: reported growth of just 2.7% looks soft, but the comparable rate was +5.7% (the gap is FX plus the LAA reclassification into EP), and management now expects the U.S. business back to mid-to-high-single-digit by year-end as personnel changes take hold.

"In Electrophysiology, the second quarter marked the beginning of an acceleration in our growth trajectory. We launched our next generation Bolt PFA catheter [...] in the US in May, and we expect to transition from limited market to a full market release in the third quarter. [...] Our EP business was up 20% in Europe in the second quarter." — Robert Ford, Chairman & CEO

Assessment: The device engine did exactly what the thesis required. EP is accelerating on the U.S. PFA ramp with a full-market release still ahead, the compounder franchises are intact, and CGM held a healthy high-single-to-9.5% pace with its catalyst stack (type-2 CMS coverage, dual-analyte sensor, international basal reimbursement) still to come. Structural Heart, the one genuine watch item entering the quarter, is turning rather than deteriorating. This is the strongest all-around device quarter in our coverage window.

Diagnostics: Cancer Dx Carries, Core Lab Accelerates in the U.S., Respiratory the Drag

Diagnostics grew 2.9% comparable (reported +42.3% on the Exact Sciences consolidation). The composition is what matters. Core Laboratory grew 3.2% worldwide, but the U.S. business accelerated to +7.5%, with the hospital-lab sub-segment up 13%, and management continues to expect the total line to lift in H2 as the China volume-based-procurement (VBP) headwind moderates from roughly a 30% decline toward a mid-single-digit decline. Cancer Diagnostics grew 13.3% on mid-teens Cologuard, and the American Cancer Society's May guideline update reaffirming Cologuard and Cologuard Plus as preferred screening options is a durable tailwind. The only drag was Rapid/Molecular at −8.0%, a purely seasonal respiratory decline that has now concluded.

"This durable demand was evident in our core laboratory results this quarter where US business grew 7.5% [...] we have got a couple different segments in our US Core Lab business [...] hospital labs [...] that business was up 13% this quarter." — Robert Ford, Chairman & CEO

Assessment: The diagnostics inflection we have tracked since Q3 2025 is intact and broadening. The reported 2.9% understates it: strip the seasonal respiratory drag and the underlying diagnostics engine (U.S. Core Lab accelerating, Cancer Dx at 13%, China easing) is set up for a materially stronger H2. Cancer Diagnostics is doing the heavy lifting the Q4 thesis underwrote, and the ACS guideline reaffirmation is a competitive moat widening at the margin.

Nutrition: Recovering Sequentially, Still Negative Year-Over-Year

Nutrition is the segment that requires the most honest framing. Sales of $2.144B were down 3.6% comparable year-over-year (pediatric −3.1%, adult −4.0%), so the segment is still contracting on a trailing basis. The recovery is real but sequential: sales rose $125M versus Q1, international pediatric turned positive at +6.5% (the highest international pediatric sales in two years), the WIC contract wins are now fully in the run-rate (Abbott is again the leader in both WIC and non-WIC), and U.S. Ensure retail consumption is up double-digits versus the 2025 exit rate. Management framed the go-forward range as 2–4% and hinted the guide could eventually prove conservative if the momentum holds.

"Nutrition, where sales finished slightly ahead of our expectations for the second consecutive quarter. Sales increased sequentially by $125 million [...] In the U.S., retail consumption of Ensure increased double digits compared to consumption levels exiting last year [...] the highest year over year consumption growth in the past year and a half." — Robert Ford, Chairman & CEO

Assessment: The reset is working on the metric that leads (consumption and volume), even as the reported YoY line stays negative on the price-and-inventory reset that is still washing through. The elasticity-targeted price strategy is producing the intended volume response, and the easy H2 comps (nutrition fell ~9% in Q4 2025) set up a swing back toward positive by year-end. We treat nutrition as improving-but-unproven: the direction is right, the YoY line is not positive yet, and Q4 is where the segment must show it can clear a positive print.

Established Pharmaceuticals: The Quiet Compounder

EPD grew 8.7% comparable to $1.499B, broad-based across India, Latin America, and Southeast Asia. Management reiterated the structural case (expanding healthcare access, aging populations, a widening biosimilars pipeline, strong brand equity) that supports sustainable high-single-digit growth, and characterized the business as reliably delivering 7–9% for five years running.

Assessment: EPD does not make headlines and does not need to. It is the ballast in the four-engine model: a high-single-digit grower with emerging-market secular tailwinds that quietly funds the innovation elsewhere in the portfolio. No change to the thesis; this is exactly what it is supposed to do.

Key Topics & Management Commentary

Overall Management Tone: The most confident and least defensive posture of the past four quarters. Management led with the word "acceleration," repeatedly anchored the story to hard monthly cadence and forward-looking volume data rather than assertion, and treated the guidance raise as a considered signal of conviction in the second half rather than a mechanical flow-through of the beat. Where Q1 had management deflecting a pointed deceleration question, this call had them leaning into the growth data unprompted; the one place they stayed carefully non-committal was the timing of the CGM reimbursement catalysts, which they were explicit they will not forecast to the quarter.

1. The Ex-Deal Deceleration Question, Answered

The single most important development is not in any one segment; it is the resolution of the debate that defined the Q1 call. Three months ago the sharpest pushback was that, stripping out Exact Sciences, the legacy-Abbott organic rate had stepped down toward ~6%, and management deflected the specific math. This quarter the comparable rate accelerated to 4.8% and, more tellingly, management volunteered that the growth rate and sales dollars improved each month within the quarter, implying an exit rate above the average.

"Our growth rate stepped up to mid single digits from where it was in the last 2 quarters of low single digits. Sales dollars, sales growth rate, all of that accelerated each month during the quarter." — Robert Ford, Chairman & CEO

Assessment: This is the quarter's thesis event. The Q1 recap said plainly that the ex-deal rate "is the number that decides the thesis" and "must re-accelerate over Q2–Q3." It re-accelerated in Q2, ahead of the deadline we set. The number is not yet at 7%, and the full-year guide leans on a steep H2, so the debate shifts from "has the base rate broken" (answered: no) to "can the H2 ramp deliver" (the new watch item). But the burden of proof has flipped from the bull to the bear.

2. Procedure Volumes and the Medtech Macro Fear

The call opened on the sector's dominant worry: negative pre-announcements from parts of the hospital sector had stoked fears of decelerating U.S. procedure volumes, variously tied to lower ACA enrollment and Medicaid disenrollment. Management's rebuttal was unusually data-grounded. Abbott's diagnostic instruments sit across the U.S. and read roughly 70% of healthcare decisions, giving a near-real-time, forward-looking view of system demand, and that data showed no slowdown, including in the states with the highest ACA disenrollment. The structural point: device demand is driven by Medicare (over two-thirds of Abbott's U.S. cardiovascular business), not Medicaid, and high-acuity care is inelastic.

"Testing volumes in the US have held up very well. Not seeing a decline, including in the states that we have seen the highest level of ACA disenrollment [...] it is not Medicaid that is a driver of med-tech surgical procedures in the United States. It is actually Medicare." — Robert Ford, Chairman & CEO

Assessment: This is why the rally was as much a sector event as an Abbott event. The diagnostic-volume read-through is a credible, differentiated data source that few peers can match, and it directly refutes the disenrollment-driven-deceleration thesis. Combined with a peer's similar message the prior day, it lifted an overhang that had been compressing the whole group's multiple. For Abbott specifically, it reinforces the "diversified model as an information advantage" argument that underpins the durable-growth case.

3. The Guidance Raise, Weighted to the Floor

Abbott raised full-year adjusted EPS to $5.45–$5.60 from $5.38–$5.58, lifting the floor $0.07 and the ceiling $0.02, and reaffirmed comparable sales growth of 6.5–7.5%. The CFO guided Q3 EPS to $1.38–$1.46. Management framed the raise as more than the in-quarter beat, citing confidence in the sustainability of the gross-margin expansion.

"We have raised it more by the beat that we had in the second quarter because we believe that the sustainability of this expansion is there." — Robert Ford, Chairman & CEO

Assessment: The shape of the raise is the signal. Lifting the floor by more than the ceiling narrows the range upward and says management has gained conviction in the downside case, not merely banked a beat. That is a higher-quality guidance action than a symmetric bump. The reaffirmed comparable-sales guide is the offsetting caution (see the H2-ramp discussion below), but on earnings the message is unambiguous confidence.

4. The Second-Half Acceleration and Its Four Drivers

The reaffirmed 6.5–7.5% full-year comparable guide requires a meaningful H2 step-up given a first half running around 4.25%. Management attributed roughly 80% of that "trajectory shift" to four businesses: Nutrition, Electrophysiology, Core Lab, and Cancer Diagnostics, each entering H2 with momentum and, in management's telling, clear line of sight to the drivers.

"The lift in the second half, 80% of that lift [...] really coming from 4 areas. Nutrition, electrophysiology, core lab, and cancer diagnostics. And each of these 4 businesses are entering with a lot of momentum and line of sight to the drivers." — Robert Ford, Chairman & CEO

Assessment: This is the crux of the remaining risk. To hit the full-year midpoint, H2 comparable growth has to run near 9.5%, a sharp acceleration off ~4.25% in H1. The mitigant is that much of it is comp-aided rather than demand-dependent: nutrition laps a ~9% Q4 2025 decline, the China VBP drag eases, and Cancer Dx ramps on care-gap seasonality that structurally concentrates in H2. Credible, but steep. The full-year sales guide is now doing more of the work than the earnings guide, and it is the number the bears will press next quarter.

5. CGM: A Healthy Plateau With Catalysts Ahead

CGM grew 9.5% to above $2.0B. Pressed on why the growth rate is below its historical teens, management reframed around a 15-year pattern of alternating modest and strong growth phases keyed to reimbursement events, and detailed the catalysts ahead: U.S. type-2 non-insulin CMS coverage (potentially this fall, unlocking ~10M Medicare beneficiaries and not in guidance), international basal-insulin reimbursement in several large markets, the Libre Duo glucose-ketone sensor (CE Mark secured), and Libre 5. The conviction signal: Abbott is in the final stages of planning a fifth manufacturing facility, a ~$1B, ~100M-sensor investment.

"You have got 75 to 80 million people around the world that could realistically be on a CGM and you have only got 15 million so far [...] The US type 2 is a huge opportunity. It is going to unlock around 10 million Medicare beneficiaries [...] it could happen in the fall." — Robert Ford, Chairman & CEO

Assessment: A 9.5% print is a modest miss against the "double-digit in Q2" the Q1 call promised, and we mark it as such. But the framing is credible: a 9% growth rate on a ~$10B run-rate business, with a stack of reimbursement catalysts management deliberately excludes from guidance, is a plateau before a step-up, not a ceiling. Committing ~$1B to a fifth plant is not the behavior of a team that sees the market maturing. We keep the Libre pillar intact, with the type-2 CMS decision as the near-term catalyst that would re-accelerate the line.

6. Gross Margin Expansion Restored

Adjusted gross margin expanded 100bp to 58.0%, the pillar that went flat in Q1 and gave the bears an opening. Management sourced it to durable levers (legacy mix, the accretive Exact Sciences addition, and the standing margin-expansion programs) and explicitly tied the guidance raise to confidence in its sustainability.

Assessment: The margin machine is back on its algorithm, and the sourcing matters: mix and structural cost programs are repeatable, whereas a one-time input-cost tailwind would not be. This is the operational underpinning of the double-digit-EPS pillar, and its restoration is a quiet but important confirmation that the Q1 flat-margin quarter was mix-and-consolidation noise rather than a structural slip.

7. Exact Sciences / Cologuard: Care-Gap Ramp and the Blood-Test Optionality

Cancer Diagnostics grew 13.3% on mid-teens Cologuard, and management reaffirmed the mid-teens full-year deal-model target with H2 higher than H1. The visibility comes from care-gap programs that help health systems hit their HEDIS and CMS star-rating targets and structurally concentrate in the back half. On the competitive question of blood-based screening, management declined to frame it as a race to lose, arguing Abbott's edge is offering both a best-in-class stool test and, eventually, a blood test, using blood as a top-of-funnel on-ramp into the higher-sensitivity Cologuard franchise.

"In May, the American Cancer Society updated its colorectal cancer screening guidelines reaffirming Cologuard and Cologuard Plus as preferred screening options. This designation reflects Cologuard's market leading accuracy and superior ability to detect cancer at earlier stages." — Robert Ford, Chairman & CEO

Assessment: The integration continues to look clean, the ACS guideline reaffirmation is a real competitive tailwind, and the care-gap seasonality gives the H2 acceleration in this business a mechanical, visible basis rather than a hopeful one. The blood-test framing (funnel, not threat) is the right strategic read: screening leadership is about sensitivity and the rescreen flywheel, both of which favor the stool-plus-blood portfolio Abbott is assembling.

8. Capital Return and the Balance Sheet

Abbott returned $2.1B to shareholders in the quarter through dividends and buybacks, and management flagged that cash generation is tracking ahead of the January forecast, creating flexibility for additional capital return. Abbott remains a Dividend King with a long compounding record.

Assessment: Not the headline of the quarter, but a steady reinforcement of the quality-compounder case. Ahead-of-plan cash generation into a still-de-rated multiple makes buybacks accretive, and the dividend growth underpins the total-return floor that supports the Outperform even if the multiple re-rates slowly.

Guidance & Outlook

The earnings guide and the sales guide are now telling slightly different stories, and the gap is the whole analytical question for the back half. On earnings, the message is unambiguous: the raise, weighted to the floor, says management has gained conviction. On sales, reaffirming 6.5–7.5% against a first half that grew roughly 4.25% comparable implies H2 comparable growth near 9.5%, a sharp ramp.

Implied H2 ramp: with Q1 at +3.7% and Q2 at +4.8%, H1 comparable growth is roughly 4.25%. To reach the 7.0% full-year midpoint, H2 comparable growth must run near 9.5%. That is achievable but not trivial, and it rests on four levers (nutrition, EP, Core Lab, Cancer Dx) all delivering together.

Why the ramp is more credible than it looks: a large share of it is comp-aided rather than demand-dependent. Nutrition laps a ~9% decline from Q4 2025, so a flat-to-modestly-positive absolute performance swings the YoY sharply higher; the China VBP diagnostics drag eases from roughly −30% toward mid-single-digit; and Cancer Dx care-gap volume structurally concentrates in H2. Layer in the EP full-market Bolt release and the exit-rate momentum management cited, and the ramp has mechanical support beyond management assertion.

Street positioning: the raised $5.525 midpoint sits modestly above where full-year consensus had been (around the old $5.48 guide midpoint), and the Q3 guide brackets the Street. The reaffirmed comparable-sales range is the line item where consensus will now concentrate its scrutiny, because it is where the residual risk lives.

Analyst Q&A Highlights

The Health of U.S. Procedure Volumes

The opening exchange, and the one most responsible for the sector-wide relief, pressed on whether Abbott sees the procedure-volume deceleration that negative hospital pre-announcements had implied. Management's answer leaned on its diagnostic-volume data as a forward-looking read and on the Medicare-not-Medicaid structure of device demand.

Q: "A theme that a lot of investors are focused on given some of the negative preannouncements out of the hospital sector is the potential for decelerating procedure volumes, particularly in the US [...] I would love to hear your view on the health and the forecast of procedure volumes in the U.S."
— Robert Marcus, JPMorgan

A: "Testing volumes in the US have held up very well. Not seeing a decline, including in the states that we have seen the highest level of ACA disenrollment [...] it is not Medicaid that is a driver of med-tech surgical procedures [...] It is actually Medicare [...] over two-thirds of our US cardio business."
— Robert Ford, Chairman & CEO

Assessment: The most consequential exchange of the call for the group, not just for Abbott. The diagnostic-volume read-through is a differentiated data source, and the structural Medicare point defuses the disenrollment thesis at its root. This is the answer that turned a good print into a sector-wide rally.

Confidence in the Second-Half Acceleration

A follow-up asked management to size its confidence in the forecast H2 acceleration and to name the drivers. The response identified the four businesses carrying roughly 80% of the lift.

Q: "It was good to see a small beat on organic sales in second quarter. The forecast includes an acceleration in third and fourth quarter. Just would love to hear how you are feeling about the confidence level in that acceleration [...] and [...] some of the key growth drivers that get you there?"
— Robert Marcus, JPMorgan

A: "The lift in the second half, 80% of that lift [...] really coming from 4 areas. Nutrition, electrophysiology, core lab, and cancer diagnostics. And each of these 4 businesses are entering with a lot of momentum and line of sight to the drivers."
— Robert Ford, Chairman & CEO

Assessment: Management named the four levers rather than hand-waving, which is the right posture, but naming them also concentrates the risk: if any of the four disappoints, the reaffirmed full-year sales guide is at stake. The exchange usefully reframes the remaining debate from base-rate durability to H2 execution.

CGM Trajectory and the Reimbursement Catalyst Stack

A recurring line of questioning on the call probed why CGM growth sits below its historical teens and when the reimbursement catalysts land. Management pushed back on reading a single country's weekly prescription data and detailed the funnel of pending coverage expansions.

Q: "I would love to double click on Libre [...] what is the outlook for the CGM business for the remainder of this year? And what is your latest thinking on the US timing for the dual glucose sensor and type 2 non-insulin coverage? [...] can these accelerate your CGM growth or just maintain the current rate?"
— Larry Biegelsen, Wells Fargo

A: "The US type 2 is a huge opportunity. It is going to unlock around 10 million Medicare beneficiaries [...] This could be a multibillion dollar opportunity, and it could happen in the fall [...] any one of these markets that goes to reimbursement expansion [...] it drastically accelerates it."
— Robert Ford, Chairman & CEO

Assessment: The 9.5% print is a modest miss versus the "double-digit" Q1 guide, and management's own framing (an 8–9% plateau between reimbursement catalysts) implicitly concedes it. But the catalyst stack is concrete and excluded from guidance, so it is optionality rather than a promise the model depends on. The type-2 CMS decision this fall is the swing factor.

Exact Sciences Care-Gap Visibility and Blood-Based Screening

A question on Exact Sciences asked how much visibility management has into the H2 care-gap ramp and whether a competitor's strong blood-test adenoma data threatens Abbott's screening leadership.

Q: "How much visibility do you have on these care gap programs in the back half stepping up for Exact Sciences? [...] do you still expect Abbott to be the market leader on the blood side even though your entry into the market will be slightly behind?"
— Vijay Kumar, Evercore ISI

A: "Care gap programs really help the health systems achieve their HEDIS credit, their CMS star ratings [...] that focus [...] tends to happen in the second half [...] we will be the only company [...] to have both stool and blood [...] doing a blood test if you are not doing anything is probably a good first step, but then you want to actually start to do it with a Cologuard test."
— Robert Ford, Chairman & CEO

Assessment: The care-gap seasonality gives the H2 Cancer-Dx acceleration a mechanical, visible basis, which de-risks the single largest of the four H2 levers. The blood-as-funnel framing is strategically sound: Abbott does not need to win the blood race outright if blood becomes an on-ramp to the higher-sensitivity, higher-rescreen Cologuard franchise.

Electrophysiology Share Aspirations and Durability

A question asked management to characterize its EP market aspirations, whether it can sustain above-market growth into next year, and how the launch cadence supports it.

Q: "You seem to be gaining traction with [Bolt] already. Could you comment on market dynamics and your aspirations [...] you are committing to growing above market in the second half. Could you talk about how that could continue into next year?"
— Matt Taylor, Jefferies

A: "We do expect to grow faster than the market [...] our growth strategy is not gonna be built off [...] 1 catheter [...] we believe that our right growth strategy is to really focus on selling the entire procedure [...] I expect global EP growth to accelerate. It is in the teens right now. It will accelerate in the second half [...] and I expect that momentum [...] to carry through to next year."
— Robert Ford, Chairman & CEO

Assessment: The "sell the whole procedure" framing (catheters plus mapping, ancillaries, ICE, introducers) is the durable version of the EP bull case, less exposed to any single competitor's catheter launch. With Bolt moving to full U.S. release and the LAA franchise now consolidated into EP, the segment has multiple legs into 2027. This is the cleanest structural growth story in the portfolio.

Structural Heart Recovery Timeline

A question pressed on when the U.S. Structural Heart franchise, softened by mitral competition, can return to trend, and whether easy 2027 comps help.

Q: "Any help just thinking through some of the strategic initiatives [...] when can the Structural Heart franchise start to see improved growth [...] can Structural Heart get back in the groove next year?"
— Josh Jennings, TD Cowen

A: "I expect structural heart by the end of the year to be in that kind of mid- to high-single-digit growth rate back to where we were before [...] It is not a price issue. It is not a product issue. It is really [...] how we think about competing in the mitral space, specifically in the US [...] We made personnel changes [...] I think by the end of the year [...] you will start to see that change in Q4."
— Robert Ford, Chairman & CEO

Assessment: Management put a timeline on the fix (mid-to-high-single-digit by Q4) and located the problem in commercial execution rather than price or product, which is the more fixable diagnosis. With international already double-digit and TAVR up 30% in H1, the issue is contained to U.S. commercial execution. The +5.7% comparable this quarter is already an improvement off the trough; Q4 is the checkpoint.

Nutrition Durability at the 2–4% Range

A question sought a state-of-the-union on nutrition, the WIC contract benefit, and the new-product cadence supporting the recovery.

Q: "The broad-out guidance commentary on nutrition, for 2% to 4%, is a nice acceleration off of the last couple of quarters. Sounds like you are getting some good momentum out of the WIC contracts. Is there an update [...] on [...] launching some new products as well as market positioning?"
— Joanne Wuensch, Citi

A: "A $125 million of sequential growth [...] the retail consumption of Ensure in the U.S. is up double digits versus our exit in 2025 [...] you could see if we can continue to maintain this momentum [...] there might be an opportunity here to kind of rethink [...] the guidance of this business. But right now [...] this is just about execution."
— Robert Ford, Chairman & CEO

Assessment: The proof points (sequential dollar growth, double-digit Ensure consumption, international pediatric turning positive) are concrete and volume-led, which is the right kind of evidence. The hint that the 2–4% guide could prove conservative is a tell that management sees upside, but the YoY line is still negative, so we hold nutrition at improving-but-unproven until it prints a positive comparable quarter.

What They're NOT Saying

1. A precise H2 comparable-growth bridge: Management named the four drivers of the second-half lift but did not quantify how much each contributes, leaving the ~9.5% implied H2 ramp resting on a qualitative "line of sight" rather than a segment-by-segment build. This is the one place the reaffirmed sales guide asks for faith.
2. An exit-rate number for the "acceleration each month": Management said the growth rate improved every month in the quarter but did not disclose the June exit rate, which is the datapoint that would most directly de-risk the H2 ramp.
3. The timing of the CGM catalysts: Type-2 CMS coverage "could happen in the fall" and international basal expansions are "coming," but management was explicit it will not forecast them to the quarter, which leaves the CGM re-acceleration date unpinned.
4. A hard date for U.S. Structural Heart to turn positive on trend: "By the end of the year" and "you will start to see that change in Q4" is directional; there is no quantified target for the U.S. sub-segment specifically, only the total-segment mid-to-high-single-digit aim.
5. The Exact Sciences path to accretion: The deal is dilutive in 2026 by the telegraphed amount, but management again offered no accretion timeline or synergy quantification, only that integration is "going very well."
6. The two undisclosed CGM programs: Management referenced "2 more programs that I am not gonna talk about for competitive reasons" as future growth drivers, flagging optionality without content, so it cannot yet be underwritten.

Market Reaction

• Pre-print setup: ABT closed at $89.27 on July 15, down 28.7% year-to-date (versus the S&P 500's +10.6%) and down 32.2% over the trailing twelve months, having ground to a multi-year trough near the bottom of its $82.56–$136.62 52-week closing range. The stock entered the print about as beaten-down and under-owned as a mega-cap compounder gets.
• Reaction-day move (July 16, BMO report): Shares gapped up 6.7% at the open ($95.29), traded a $94.99–$101.87 range, and closed at $98.83, up 10.7% ($9.56), the sharpest single-session gain in years and a decisive break of the downtrend.
• Volume: 32.8M shares versus a 13.1M 30-day average, a 2.5x spike, confirming real repositioning rather than a thin-tape move.
• Index backdrop: The S&P 500 fell 0.5% on the session, so the entire 10.7% gain was idiosyncratic, and medtech peers firmed alongside on the shared procedure-volume relief.

An 11% single-day gain on a diversified $150B+ healthcare name is a positioning event as much as a fundamental one. Three things cleared at once. First, the print delivered the specific proof the bears had demanded: comparable growth accelerated, resolving the ex-deal-deceleration question that had hung over the Q1 call. Second, the guidance raise, weighted to the floor, and the 100bp gross-margin expansion rebuilt confidence in the earnings algorithm. Third, and most powerful given the setup, the diagnostic-volume commentary lifted a sector-wide procedure-volume fear rather than merely an Abbott-specific one.

The magnitude of the move is a function of how one-sided the positioning had become. A stock down 32% over twelve months, making fresh lows on every print, had priced in a permanent deceleration and an unquantified macro risk. When the quarter disproved both at once, the re-rate was violent because there was little offsetting supply. The move took the multiple from roughly 16x to roughly 18x forward, from absurdly cheap to merely cheap, which is why we read the pop as the start of a re-rating rather than the exhaustion of one.

Owning the arc: we upgraded in January at $108.61, watched the stock fall to a Q1 low of $95.47 and lower still into this print, and said plainly at Q1 that the timing was early and the ex-deal rate had to re-accelerate to validate the call. It re-accelerated. The drawdown was real and we do not retcon it, but the forward case is now being confirmed by the tape rather than fought by it.

Street Perspective

Debate: Is the Re-Acceleration Real or a One-Quarter Comp Artifact?

Bull view: Comparable growth accelerated to 4.8% with the monthly cadence improving through the quarter, gross margin expanded 100bp, and management raised the guide. The ex-deal-deceleration thesis is dead; the base rate is re-accelerating toward 7% exactly as the diversified-portfolio model predicts once the transitory drags clear.

Bear view: One quarter of +4.8% is still below the 6.5–7.5% full-year guide, and reaching the midpoint requires a ~9.5% H2 that leans heavily on comp effects. If nutrition stays negative or Core Lab China lingers, the reaffirmed sales guide is the number that breaks, and the "acceleration" was a soft-comp illusion.

Our take: Bull, with the debate correctly reframed. The base-rate question (has the franchise structurally slowed) is answered no; the exit rate is above the average and margins confirm operating health. The residual risk has narrowed to H2 execution on four named levers, most of it comp-aided. That is a materially better risk posture than the open-ended deceleration fear we carried into this print.

Debate: After an 11% Pop, Is the Easy Money Made?

Bull view: Even post-pop, ABT trades near 18x the raised FY2026 midpoint and ~16x a recovering 2027, well below its own multi-year average of low-to-mid-20s and below diversified-medtech peers, for a franchise that just re-accelerated, expanded margins, raised the guide, and carries a fifth-CGM-plant, care-gap-ramp, type-2-CMS option stack. The re-rate has room.

Bear view: The quarter was good but the 11% move already captured it; the stock round-tripped from oversold to fairly valued in a session, and the H2 ramp plus CGM plateau leave little margin for error at a higher multiple. Buying after the pop is chasing.

Our take: Bull, with eyes open. The pop took the stock from a distressed multiple to a still-below-average one, not to a full one. For a Dividend King re-accelerating to 7%+ with double-digit underlying EPS, restored margins, and a diagnostics/cancer optionality the guide does not lean on, ~18x is not where this franchise tops out. The easy oversold-bounce is made; the fundamental re-rating is not.

Debate: Does the Diagnostic-Volume Read-Through Change the Medtech Macro?

Bull view: Abbott's instruments read roughly 70% of healthcare decisions in near-real-time and showed no procedure-volume slowdown, even in high-disenrollment states, corroborating a peer's message. The disenrollment-driven-deceleration fear that compressed the group's multiple is empirically refuted, and the group re-rates.

Bear view: One data source and one quarter do not settle a macro debate; if enrollment pressures build through 2027, the lagged effect on elective procedures could still appear, and Abbott's high-acuity mix may not represent the more elective-exposed peers.

Our take: Lean bull. The diagnostic-volume data is a genuinely differentiated, forward-looking read that few peers can offer, and the Medicare-not-Medicaid structural point is sound for high-acuity device demand. It does not eliminate a slower-burn 2027 risk, but it removes the acute overhang the market had priced, and for Abbott specifically it reinforces the information-advantage that underpins the durable-growth case.

Model & Valuation Framework

Valuation framework: At $98.83 post-print, Abbott trades at ~17.9x the $5.525 FY2026 midpoint and ~16x a recovering 2027 EPS of roughly $6.15. That is still below the franchise's own multi-year average (low-to-mid-20s) and below diversified-medtech peers, despite a quarter that re-accelerated the top line, expanded margins 100bp, raised the earnings guide, and resolved the central bear point. The base-case target of ~$119 (≈21.5x FY2026 / ≈19x 2027) implies ~20% upside; the bull case (~$135) implies ~37%; the bear case (~$92) implies ~7% downside. The up-to-down skew is roughly 3:1, and the base case now rests on confirmed re-acceleration rather than hoped-for re-acceleration.

Why maintain Outperform after an 11% pop: the move took the multiple from distressed (~16x) to merely cheap (~18x), not to full. The thesis conditions we set at Q1 were met: the ex-deal rate re-accelerated, EP kept accelerating, nutrition volume kept recovering, diagnostics stayed on its path, gross margin came back, and the guide was raised. A stock that just confirmed its thesis and still trades below its historical multiple with a growing dividend and buyback is not one to sell into the first day of a re-rating.

What would move us to Hold: the H2 comparable ramp visibly failing (a Q3 that decelerates rather than steps up), nutrition staying negative into Q4, or the multiple running to the low-20s before the H2 fundamentals confirm. What would move us to Underperform: evidence the re-acceleration was a one-quarter comp artifact and the base rate resettles below 5%, a renewed procedure-volume deceleration in the diagnostic data, or a structural CGM stall with the type-2 CMS catalyst denied.

Thesis Scorecard Post-Earnings

We score this quarter against the standing thesis. The Q1 commitments we set to watch were: the ex-deal growth re-accelerating toward 7%, CGM returning to double-digit, the nutrition volume trajectory, Core Lab H2 acceleration, U.S. Structural Heart stabilizing, the Volt U.S. ramp broadening, Exact Sciences integration plus CMS news, and Q2 EPS versus the $1.25–$1.31 guide with FY reaffirmation. The scorecard:

Overall: The thesis strengthened, and its central open question resolved favorably. The ex-deal deceleration point (Bear-6), which the Q1 recap called the number that decides the thesis, moved from Emerging toward Contained as comparable growth accelerated to +4.8% with an improving monthly cadence. The margin-expansion pillar (Bull-4) was restored with a 100bp gross-margin gain, EP kept accelerating, Structural Heart turned, and Cancer Diagnostics confirmed the new vertical. The offsets are honest but contained: nutrition is still negative year-over-year, CGM came in a hair below its guide, and the reaffirmed full-year sales guide now leans on a steep, if comp-aided, H2 ramp. On balance, the franchise is executing the plan and the market has begun to pay for it.

Action: Maintain Outperform, raise conviction. The early upgrade is working; the thesis was confirmed rather than merely defended this quarter. The next thing to prove is the H2 comparable ramp and the CGM cadence into the type-2 CMS decision.

Bottom Line: The Early Call Is Working

Rating decision: We maintain Outperform on Abbott and raise our conviction. The scoreboard we owned last quarter was ugly: we upgraded in January at $108.61 and the stock fell to a multi-year trough near $89 into this print. But a rating is a forward judgment, and the forward case was confirmed this quarter, not merely defended. The ex-deal growth rate we said had to re-accelerate re-accelerated; the margin pillar we said had to come back came back; the guide went up.

The quarter did four things that matter. It resolved the central bear point, with comparable growth accelerating to 4.8% and a monthly cadence that improved through the quarter. It rebuilt the margin story, with adjusted gross margin expanding 100bp to 58.0% on durable levers. It raised the earnings guide in a way that de-risked the downside, lifting the floor more than the ceiling. And it lifted a sector-wide macro fear, with diagnostic-volume data refuting the procedure-volume-deceleration thesis at its root. The stock rose 10.7% on 2.5x volume because all of that landed against positioning that had priced the opposite.

At ~18x the raised FY2026 midpoint and ~16x a recovering 2027, this is still below where a re-accelerating Dividend King with double-digit underlying EPS, restored margins, an accelerating diagnostics-and-cancer franchise, and an unpriced CGM-reimbursement option stack should trade. The disciplined move after being early and patient is not to declare victory and ring the register on the first up day; it is to stay long, let the H2 ramp confirm, and give the re-rating room to run.

What we are watching into Q3 2026 (October):